### **AMENDMENTS TO THE CLAIMS**

## 1. (Currently Amended) A compound represented by the formula (I):

$$\begin{array}{c}
R^{2} \\
R^{3} \\
R-N \\
X
\end{array}$$
(I)

wherein R<sup>2</sup> and R<sup>3</sup> are the same or different and each is C2-C4 alkyl, C2-C4 alkenyl, C1-C4 alkoxyC1-C4 alkyl, optionally substituted aminoC1-C4 alkyl, or C3-C6 cycloalkylC1-C4 alkyl; or

R<sup>2</sup> and R<sup>3</sup> are taken together with the adjacent carbon atom to form an optionally substituted 5 to 8 membered non-aromatic carbocyclic ring or an optionally substituted 5 to 8 membered non-aromatic heterocyclic ring;

R<sup>4</sup> is C1-C6 alkyl, hydroxyC1-C6alkyl, optionally substituted aminoC1-C6alkyl, or C1-C6 alkoxyC1-C6 alkyl;

X is an oxgen atom or a sulfur atom;

A is the a group of the formula:

$$(R^1)_n$$
 $(R^1)_n$ 
 $(R^1)_n$ 
 $(R^1)_n$ 
 $(R^1)_n$ 

wherein R<sup>1</sup> is, same or different, alkyl, alkoxy, alkylthio, optionally substituted amino, optionally substituted aryl, optionally substituted aryloxy, optionally substituted aralkyloxy, cycloalkyl, a halogen atom, hydroxy, nitro, haloalkyl, haloalkoxy, optionally substituted carbamoyl, carboxy, alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl, alkoxylalkyl, alkylthioalkyl, optionally substituted aminoalkyl, alkoxylminoalkyl, alkoxyalkoxy, alkylthioalkoxy, alkoxycarbonylalkoxy, carboxyalkoxy, alkylsulfonyloxy, optionally substituted heteroaryl, an optionally substituted non-aromatic heterocyclic group, cyano, cyanoalkoxy, or a group of the formula: -C(=O)-R<sup>H</sup> wherein

R<sup>H</sup> is a hydrogen atom, alkyl, optionally substituted aryl, or an optionally substituted non-aromatic heterocyclic group;

W is C2-C6-alkylene which may contain an optionally substituted heteroatom(s) or C2-C4 alkenylene which may contain an optionally substituted heteroatom(s) -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, 
CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -OCH<sub>2</sub>O-, -OCH<sub>2</sub>CH<sub>2</sub>O-, -N(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, or -CH=CH-CH=CH-;

n is an integer of 0 to 7;

wherein the optionally substituted amino is non-substituted amino, C1-C4 alkylamino, (C1-C4 alkyl)carbonylamino, aryl carbonylamino, N-(C1-C4 alkyl)carbonyl-C1-C4 alkylamino, aralkylamino, C1-C4 alkylsulfonylamino, C2-C4 alkenyloxycarbonylamino, (C1-C4 alkoxy)carbonylamino, C2-C4 alkenylamino, arylcarbonylamino, or heteroarylcarbonylamino,

the substituent of optionally substituted carbamoyl is selected from the group consisting of alkyl and acyl, and,

the substituent of non-aromatic carbocyclic ring, non-aromatic heterocyclic ring, aryl, aryloxy, aralkyloxy, heteroaryl, and a non-aromatic heterocyclic group is selected from the group consisting of hydroxy, carboxy, a halogen atom, haloalkyl, haloalkoxy, alkyl, alkenyl, formyl, acyl, alkynyl, cycloalkyl, alkoxy, alkoxycarbonyl, nitro, nitroso, oxo, optionally substituted amino, azido, aryl, aryloxy, cyano, isocyano, isocyanato, thiocyanato, isothiocyanato, mercapto, alkylthio, alkylsulfonyl, arylsulfonyl, optionally substituted carbamoyl, sulfamoyl, formyloxy, haloformyl, oxalo, thioformyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, sulfoamino, hydrazino, ureido, amidino, guanidino, formyloxy, thioxo, alkoxyalkoxy, and alkylthioalkoxy,

a pharmaceutically acceptable salt, or a solvate thereof.

2. (Original) The compound according to Claim 1 wherein R<sup>2</sup> and R<sup>3</sup> are taken together with the adjacent carbon atom to form an optionally substituted 5 to 6 membered carbocyclic ring, a pharmaceutically acceptable salt, or a solvate thereof.

# 3. (Cancelled)

4. (Currently Amended) A compound of the formula (II):

$$\begin{array}{c|c} (R^1)_n & \stackrel{\textstyle R^2}{\searrow} R^3 \\ \stackrel{=}{\searrow} N & \stackrel{\textstyle N}{\searrow} S \\ \stackrel{\scriptstyle \times}{\searrow} R^4 \end{array} \tag{II}$$

wherein R<sup>1</sup> is, same or different, alkyl, alkoxy, optionally substituted amino, a halogen atom, hydroxy, haloalkyl, haloalkoxy, cyano, or alkoxycarbonylalkoxy;

each of R<sup>2</sup> and R<sup>3</sup> is, same or different, C2-C4 alkyl; or

 $R^2$  and  $R^3$  are taken together with the adjacent carbon atom to form 5 to 6 membered cycloalkane;

R<sup>4</sup> is C1-C6 alkyl;

X is an oxgen atom or a sulfur atom;

n is an integer of 0 to 7;

wherein the optionally substituted amino is non-substituted amino, C1-C4 alkylamino, (C1-C4 alkyl)carbonylamino, aryl carbonylamino, N-(C1-C4 alkyl)carbonyl-C1-C4 alkylamino, aralkylamino, C1-C4 alkylsulfonylamino, C2-C4 alkenyloxycarbonylamino, (C1-C4 alkoxy)carbonylamino, C2-C4 alkenylamino, arylcarbonylamino, or heteroarylcarbonylamino, a pharmaceutically acceptable salt, or a solvate thereof.

- **5.** (Original) The compound according to Claim 4 wherein R<sup>1</sup> is a fluorine atom, a chlorine atom, dimethylamino, cyano, or t-butoxycarbonylmethoxy, a pharmaceutically acceptable salt, or a solvate thereof.
- **6. (Original)** The compound according to Claim 4 or 5 wherein n is 0 or 1, a pharmaceutically acceptable salt, or a solvate thereof.

7. (Currently Amended) A compound of the formula (II):

$$\begin{array}{c|c}
(R^1)_n & \stackrel{}{\stackrel{}{\stackrel{}}{\stackrel{}}} & R^3 \\
 & \stackrel{}{\stackrel{}{\stackrel{}}{\stackrel{}}} & N & \\
 & \stackrel{}{\stackrel{}{\stackrel{}}{\stackrel{}}} & R^4 \\
\end{array}$$
(III)

wherein R<sup>1</sup> is, same or different, alkyl, alkoxy, optionally substituted amino, a halogen atom, hydroxy, haloalkyl, haloalkoxy, cyano, or alkoxycarbonylalkoxy;

each of R<sup>2</sup> and R<sup>3</sup> is, same or different, C2-C4 alkyl; or

R<sup>2</sup> and R<sup>3</sup> are taken together with the adjacent carbon atom to form 5 to 6 membered cycloalkane;

R<sup>4</sup> is C1-C6 alkyl;

X is an oxgen atom or a sulfur atom;

Z is -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, or -OCH<sub>2</sub>CH<sub>2</sub>O-;

n is an integer of 0 to 3;

wherein the optionally substituted amino is non-substituted amino, C1-C4 alkylamino, (C1-C4 alkyl)carbonylamino, aryl carbonylamino, N-(C1-C4 alkyl)carbonyl-C1-C4 alkylamino, aralkylamino, C1-C4 alkylsulfonylamino, C2-C4 alkenyloxycarbonylamino, (C1-C4 alkoxy)carbonylamino, C2-C4 alkenylamino, arylcarbonylamino, or heteroarylcarbonylamino, a pharmaceutically acceptable salt, or a solvate thereof.

- **8. (Original)** The compound according to Claim 7 wherein Z is -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, a pharmaceutically acceptable salt, or a solvate thereof.
- **9. (Original)** The compound according to Claim 7 wherein Z is -OCH<sub>2</sub>CH<sub>2</sub>O-, a pharmaceutically acceptable salt, or a solvate thereof.
- 10. (Previously Presented) The compound according to Claim 7 wherein n is 0, a pharmaceutically acceptable salt, or a solvate thereof.

- 11. (Original) The compound according to any one of Claim 4 or 7 wherein R<sup>2</sup> and R<sup>3</sup> are taken together with the adjacent carbon atom to form 6 membered cycloalkane, a pharmaceutically acceptable salt, or a solvate thereof.
- 12. (Previously Presented) The compound according to any one of Claims 1, 4 and 7 wherein each of R<sup>2</sup> and R<sup>3</sup> is, same or different, C2-C3 alkyl, a pharmaceutically acceptable salt, or a solvate thereof.
- 13. (Previously Presented) The compound according to any one of Claims 1, 4 and 7 wherein R<sup>4</sup> is methyl or ethyl, a pharmaceutically acceptable salt, or a solvate thereof.
- **14.** (Currently Amended) A pharmaceutical composition which contains the compound according to any one of Claims 1, 4 and 7, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient and a pharmaceutically acceptable carrier.

### 15. to 19. (Cancelled)

20. (Currently Amended) A method for treating a disease related to a cannabinoid receptor pain which comprises administering the compound according to any one of Claims 1, 4 and 7, a pharmaceutically acceptable salt, or a solvate thereof.

#### 21. to 25. (Cancelled)

**26.** (New) A method for treating pruritus which comprises administering the compound according to any one of Claims 1, 4 and 7, a pharmaceutically acceptable salt, or a solvate thereof.

27. (New) A method for treating bronchodilation which comprises administering the compound according to any one of Claims 1, 4 and 7, a pharmaceutically acceptable salt, or a solvate thereof.